(Circulation. 2000;102:28.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions
From the Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio.
Correspondence to Dr Eric J. Topol, Department of Cardiology, F-25, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail topole{at}ccf.org
Background—Previous trials testing stents compared with balloon angioplasty excluded patients with complex lesions and did not assess the effect of adjunctive platelet IIb/IIIa inhibition. This analysis sought to assess the effect of stenting and abciximab specifically for patients with complex lesions.
Methods and Results—Patients with complex lesions (long, tandem, severely calcified, restenotic, thrombotic, or ostial; total occlusions; bifurcations; saphenous vein grafts; and multivessel interventions) from the Evaluation of PTCA to Improve Long-Term Outcome by c7E3 GP IIb/IIIa Receptor Blockade (EPILOG) and the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trials were included in the analysis. The 1-year combined death or myocardial infarction rates in the 4 treatment groups were as follows: balloon angioplasty/placebo, 14.2%; stent/placebo, 15.8%; balloon angioplasty/abciximab, 7.6%; and stent/abciximab, 8.0% (P<0.001). Death rates were 3.2%, 3.1%, 2.1%, and 0.5%, respectively (P=0.03). The incidence of target vessel revascularization at 1 year was 30.5%, 18.0%, 24.4%, and 19.7% in the 4 groups, respectively (P<0.001). After adjustment for baseline differences, multivariate analysis demonstrated that the rate of death or myocardial infarction was independently reduced by balloon angioplasty/abciximab (hazard ratio, 0.51; P<0.001) and stent/abciximab (hazard ratio, 0.60; P=0.02) but was not affected by the use of stents alone. Conversely, target vessel revascularization was reduced by stent/placebo (hazard ratio, 0.53; P<0.001), stent/abciximab (hazard ratio, 0.58; P<0.001), and balloon angioplasty/abciximab (hazard ratio, 0.74; P=0.006) compared with balloon angioplasty/placebo, respectively.
Conclusions—The combination of stenting and abciximab during percutaneous coronary interventions for patients with angiographically complex lesions confers additive long-term benefit with respect to death, myocardial infarction, and target vessel revascularization.
Key Words: lesion • angioplasty • stents • platelets • inhibitors
This article has been cited by other articles:
 |
|
 |
|
  H. K. Win, A. E. Caldera, K. Maresh, J. Lopez, C. S. Rihal, M. A. Parikh, J. F. Granada, S. Marulkar, D. Nassif, D. J. Cohen, et al. Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents JAMA, May 9, 2007; 297(18): 2001 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Drenth, N. J.G.M. Veeger, J. G. Grandjean, M. A. Mariani, A. J. van Boven, and P. W. Boonstra Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? Eur. J. Cardiothorac. Surg., April 1, 2004; 25(4): 567 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Lemos, C.-h. Lee, M. Degertekin, F. Saia, K. Tanabe, C. A. Arampatzis, A. Hoye, M. van Duuren, G. Sianos, P. C. Smits, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: Insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2093 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Drenth, N. J. G. M. Veeger, J. B. Winter, J. G. Grandjean, M. A. Mariani, A. d J. Boven van, and P. W. Boonstra A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1955 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Drenth, J. B. Winter, N. J. G. M. Veeger, S. H. J. Monnink, A. J. van Boven, J. G. Grandjean, M. A. Mariani, and P. W. Boonstra Minimally invasive coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty with stenting in isolated high-grade stenosis of the proximal left anterior descending coronary artery: Six months' angiographic and clinical follow-up of a prospective randomized study J. Thorac. Cardiovasc. Surg., July 1, 2002; 124(1): 130 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Serruys, D. P. Foley, M.-J. Suttorp, B. J. W. M. Rensing, H. Suryapranata, P. Materne, A. van den Bos, E. Benit, A. Anzuini, W. Rutsch, et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: Final results of the additional value of nir stents for treatment of long coronary lesions (ADVANCE) study J. Am. Coll. Cardiol., February 6, 2002; 39(3): 393 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt, M. E. Bertrand, P. B. Berger, P. L. L'Allier, I. Moussa, J. W. Moses, G. Dangas, M. Taniuchi, J. M. Lasala, D. R. Holmes, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting J. Am. Coll. Cardiol., January 2, 2002; 39(1): 9 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA, September 27, 2000; 284(12): 1549 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Greater Benefit of Stents with Abciximab in Complex Lesions Journal Watch Cardiology, September 15, 2000; 2000(915): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Z. Kaposzta, J. F. Martin, and H. S. Markus Switching off Embolization From Symptomatic Carotid Plaque Using S-Nitrosoglutathione Circulation, March 26, 2002; 105(12): 1480 - 1484. [Abstract] [Full Text] [PDF]
|
|